ENGENDERING THE NEXT SIGNIFICANT SHIFT IN WOMEN’S HEALTH DIRECTIVES-

Sherrie Palm carves the trail to de-stigmatize pelvic organ prolapse as she educates and inspires regarding the quality of life impact of POP, a common but rarely acknowledged women’s health condition impacting an estimated 50% of women. Sherrie Palm is the Founder/CEO of APOPS, Association for Pelvic Organ Prolapse Support, author of 3 editions of the award-winning book Pelvic Organ Prolapse: The Silent Epidemic, an internationally recognized speaker, women’s health advocate, Key Opinion Leader, and prolific writer regarding POP physical, emotional, social, sexual, fitness, and employment quality of life impact. Sherrie has presented speeches nationally and internationally to physician, research, academic, corporate, policy and patient audiences since 2011. Her points of focus are raising awareness of the next significant evolution in women’s health awareness, screening, practice, and policy, increasing global POP understanding, advancing POP patient guidance and support structures, and bridge building within patient advocacy, white coat, and white collar sectors toward the evolution of women’s pelvic health and POP best practices. Recognizing a need to shift the global view of pelvic organ prolapse, Sherrie Palm takes steps to pioneer change. Cognizant of the diverse and sensitive needs of her audience regarding this common, cryptic women’s health concern, Sherrie delicately places all the cards on the table to disclose aspects of vaginal health that few discuss. Sherrie’s capacity to respectfully and compassionately answer all questions posed during speaking engagements endears her to the audience. Sherrie’s engagement in POP projects and protocol enables patient voice to be an integral part of women’s health and wellness evolution. Sherrie presented to the FDA Obstetrics and Gynecology Advisory Committee Panel transvaginal mesh complication meetings in 2011 and 2019, sat on the Pelvic Floor Disorders Stakeholder Advisory Committee from 2011-2013, and currently sits on the FDA Medical Device Epidemiology Network (MDEpiNET) committee.